MedTrace Logo

Intrathecal Bolus Doses of Ziconotide

NCT01373983 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 26

Last updated 2014-12-30

No results posted yet for this study

Summary

The purpose of this study is to evaluate if the effect of ziconotide can be tested by intrathecal bolus doses.

Conditions

Interventions

DRUG

Ziconotide

1.25 or 2.5 mcg or 3.75 mcg i.t. according to an algorithm

Sponsors & Collaborators

  • University Hospital, Linkoeping

    lead OTHER

Principal Investigators

  • Emmanuel Bäckryd, MD · Pain and Rehabilitation Centre, University Hospital, Linköping, Sweden

Study Design

Allocation
NA
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-08-31
Primary Completion
2014-12-31
Completion
2014-12-31

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01373983 on ClinicalTrials.gov